HerbertIHurwitzMD

Oncology • Durham, NC

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Are you Dr. Hurwitz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 99 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
2100 Erwin Rd
Durham, NC 27705
Phone+1 919-620-4467

Summary

Dr. Herbert Hurwitz, MD is an oncologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina. He is an Associate Professor at Duke University School of Medicine.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1988 - 1991
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1988

Certifications & Licensure

NC State Medical License 1996 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2007 Mar 01
Completed
Phase 1
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) Start of enrollment: 2007 Nov 01
Completed
Phase 1
Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Start of enrollment: 2007 Oct 01
Completed
Phase 2
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. Start of enrollment: 2009 Jul 01
Completed
Phase 1
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors Start of enrollment: 2009 Mar 01
Completed
Phase 1
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib Start of enrollment: 2009 May 01
Completed
Phase 1
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors Start of enrollment: 2010 Mar 01
Completed
Phase 1
A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 Start of enrollment: 2010 Apr 01
Completed
Phase 1
Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil Start of enrollment: 2010 Jun 01
Completed
Phase 1
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function Start of enrollment: 2011 Nov 01
Completed
Phase 1
Dose Escalation Study of Pazopanib Plus TH-302 Start of enrollment: 2011 Dec 01
Completed
Phase 1
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Join now to see all

Publications & Presentations

PubMed

55 citations
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, Thorvardur R Halfdanarson, Heinz-Josef Lenz
JAMA Network Open. 2022-02-01
8233 citations
BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John D. Hainsworth
The New England Journal of Medicine. 2004-06-03
17 citations
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Jeffrey M. Clarke, Herbert Hurwitz
Nature Reviews. Clinical Oncology. 2013-01-01

Grant Support

Wound Angiogenesis As A Biomarker For Tumor AngiogenesisNational Cancer Institute2006–2010
Anti-Vegf In Tumors &Wounds: Efficacy VS ToxicityNational Cancer Institute2006–2010
Biomarker And Clinical Evaluation Of Bevacizumab (AVASTIN) To Determine The RoleNational Center For Research Resources2005
New Clinical Biomarker For Cancer--Wound AngiogenesisNational Cancer Institute2000–2005
Nitric Oxide In Anti-Vegf TherapyNational Center For Research Resources2004
Does NO Mediate Clinical Anti-Vegf Vascular EffectsNational Cancer Institute2003–2004
PH I: Two Week PO Administration SCH 66336 Advanced CancerNational Center For Research Resources1999–2002
PH 1 Xrt+5 Fu+Eniluracil--Advanced Unresectable Upper GI MalignanciesNational Center For Research Resources1999–2002
Bioequivalence Combination 776c85/5fu Pill &Individual 776c85 &5fu PillNational Center For Research Resources1998–2002
Surrogate Markers Of Angiogenesis In Patients Treated With Anti-Angiogenic AgentsNational Center For Research Resources2000
Phase I Trial To Evaluate The Safety &Tolerability Of Topoisomerase I InhibitorNational Center For Research Resources2000
Evaluate Potential Surrogate Markers Of Angiogenesis In Normal VolunteersNational Center For Research Resources2000

Professional Memberships

American Society of Clinical Oncology - ASCO
Member